AKRO

29.56

5.23% 1.47

Handel nachbörslich: 29.56

Akero Therapeutics Inc (AKRO)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt AKRO? Forum Prognose

Schlusskurs vom Vortag:

$28.09

Offen:

$28.72

24-Stunden-Volumen:

1.20M

Relative Volume:

2.26

Marktkapitalisierung:

$2.06B

Einnahmen:

Nettoeinkommen (Verlust:

$-179.27M

KGV:

-11.55

EPS:

-2.56

Netto-Cashflow:

$-155.88M

1W Leistung:

-10.53%

1M Leistung:

-5.35%

6M Leistung:

+48.39%

1J Leistung:

+89.24%

1-Tages-Spanne:

$28.44

$29.85

1-Wochen-Bereich:

$27.05

$34.54

52-Wochen-Spanne:

$15.32

$37.00

Akero Therapeutics Inc Stock (AKRO) Company Profile

Firmenname

Akero Therapeutics Inc

Sektor

Healthcare (1196)

Branche

Biotechnology (683)

Telefon

650-487-6488

Adresse

601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO, CA

Mitarbeiter

Twitter

@akerotx

Nächster Verdiensttermin

2024-11-11

Neueste SEC-Einreichungen

AKRO's Discussions on Twitter

Vergleichen Sie AKRO mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
AKRO	29.56	2.06B	0	-179.27M	-155.88M	-2.56
VRTX	467.01	119.87B	10.63B	-479.80M	-1.35B	13.33
REGN	762.00	83.27B	13.85B	4.65B	3.32B	35.06
ARGX	567.90	33.96B	1.86B	-40.29M	-1.28B	-4.16
ALNY	232.27	30.18B	2.09B	-332.26M	16.06M	-4.14
BNTX	101.87	24.42B	3.30B	-501.07M	1.03B	11.54

Akero Therapeutics Inc Stock (AKRO) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-04-22	Fortgesetzt	BofA Securities	Neutral
2023-09-19	Eingeleitet	Cantor Fitzgerald	Overweight
2023-08-28	Eingeleitet	UBS	Buy
2023-01-27	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2022-09-14	Hochstufung	Evercore ISI	In-line → Outperform
2021-10-19	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2021-09-10	Eingeleitet	BofA Securities	Buy
2021-02-26	Eingeleitet	Guggenheim	Buy
2020-09-10	Eingeleitet	Morgan Stanley	Overweight
2020-07-20	Bestätigt	H.C. Wainwright	Buy
2020-07-07	Eingeleitet	Chardan Capital Markets	Buy
2020-07-01	Bestätigt	H.C. Wainwright	Buy
2020-03-02	Eingeleitet	H.C. Wainwright	Buy
2020-02-10	Eingeleitet	Canaccord Genuity	Buy
2019-07-15	Eingeleitet	Evercore ISI	Outperform
2019-07-15	Eingeleitet	JP Morgan	Overweight
2019-07-15	Eingeleitet	Jefferies	Buy
2019-07-15	Eingeleitet	ROTH Capital	Buy

Alle ansehen

Akero Therapeutics Inc Aktie (AKRO) Neueste Nachrichten

08:32 AM

HC Wainwright Reaffirms "Buy" Rating for Akero Therapeutics (NASDAQ:AKRO) - MarketBeat

08:32 AM

07:34 AM

Citigroup Begins Coverage on Akero Therapeutics (NASDAQ:AKRO) - MarketBeat

07:34 AM

Nov 15, 2024

Akero Therapeutics (NASDAQ:AKRO) Shares Down 6.4%What's Next? - MarketBeat

Nov 15, 2024

Akero Therapeutics, Inc. (NASDAQ:AKRO) Position Boosted by Simplify Asset Management Inc. - MarketBeat

Nov 15, 2024

Akero Therapeutics to Showcase New Analyses of Phase 2b - GlobeNewswire

Nov 15, 2024

Akero Therapeutics, Inc. to Showcase New Analyses of Phase 2b Harmony Study in Presentations at 75th Annual AASLD The Liver Meeting®? 2024 - Marketscreener.com

Nov 15, 2024

Akero Therapeutics, Inc. (NASDAQ:AKRO) Sees Large Decline in Short Interest - MarketBeat

Nov 15, 2024

Janus Henderson Group PLC's Strategic Acquisition of Akero Thera - GuruFocus.com

Nov 15, 2024

Nov 14, 2024

RTW INVESTMENTS, LP Expands Stake in Akero Therapeutics Inc - GuruFocus.com

Nov 14, 2024

Nov 13, 2024

Akero Therapeutics to Present at the Jefferies London Healthcare Conference - GlobeNewswire

Nov 13, 2024

Akero Therapeutics to Present at Jefferies London Healthcare Conference | AKRO Stock News - StockTitan

Nov 13, 2024

ALKEON CAPITAL MANAGEMENT LLC Reduces Stake in Akero Therapeutics Inc - GuruFocus.com

Nov 13, 2024

FY2028 EPS Forecast for Akero Therapeutics Raised by Analyst - MarketBeat

Nov 13, 2024

Akero Therapeutics (NASDAQ:AKRO) Earns “Buy” Rating from HC Wainwright - Defense World

Nov 13, 2024

Nov 12, 2024

Akero Therapeutics Advances in MASH Treatment Trials - Yahoo Finance

Nov 12, 2024

Nov 11, 2024

Akero Therapeutics Reports Third Quarter 2024 Financial Results and Business UpdateAkero Therapeutics, Inc. made significant strides in the third quarter of 2024, announcing the dosing of the first patient in the Phase 3 SYNCHRONY Outcomes study of i - Defense World

Nov 11, 2024

Nov 09, 2024

Akero Therapeutics (NASDAQ:AKRO) Releases Earnings Results, Misses Estimates By $0.15 EPS - MarketBeat

Nov 09, 2024

Nov 08, 2024

Akero Therapeutics executive sells $351,890 in stock - Investing.com

Nov 08, 2024

Akero Therapeutics executive sells $351,890 in stock By Investing.com - Investing.com Australia

Nov 08, 2024

Wellington Management Group LLP's Strategic Acquisition of Akero Therapeutics Shares - GuruFocus.com

Nov 08, 2024